Efficacy and safety of liposome-paclitaxel and carboplatin based concurrent chemoradiotherapy for locally advanced lung squamous cell carcinoma
- 128 Downloads
The aim of this study was to evaluate the efficacy and toxicities of liposome-paclitaxel and carboplatin concurrent with radiotherapy for locally advanced lung squamous cell carcinoma (LSCC).
The clinical data of 38 patients with locally advanced LSCC treated with liposome-paclitaxel based concurrent chemoradiotherapy were collected and reviewed. The overall response, toxicities, progression-free survival and overall survival were analyzed with SPSS software.
The efficacy of treatment was classified as complete remission in 4 cases (10.5%), partial remission in 22 cases (57.9%) and stable disease in 12 cases (31.6%). The objective response rate was 68.4% (26/38). The most common types of hematological toxicities were anemia (65.7%) and leukopenia (57.9%), but all the events were transient. No paclitaxel-induced allergic reactions occurred during the treatment. The median PFS and OS time were 17.0 and 29.0 months.
Liposome-paclitaxel and carboplatin concurrent with radiotherapy showed a significant antitumor effect to LSCC with manageable toxicities. Further clinical investigation are warranted to evaluate the efficacy of this regimen.
KeywordsNon-small cell lung carcinoma Lung squamous cell carcinoma Liposome-paclitaxel Chemoradiotherapy
We are grateful to the patients who are included in this study. This study was supported by grants from the Nature Science Foundation of Zhejiang Province (No. LY14H160012).
Compliance with ethical standards
Conflict of interest
None of the authors have conflicts of interest to declare.
Research involving human participants and/or animals
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 3.Bille A, Ahmad U, Woo KM, Suzuki K, Adusumilli P, Huang J, Jones DR, Rizk NP (2016) Detection of recurrence patterns after wedge resection for early stage lung cancer: rationale for radiologic follow-up. Ann Thoracic Surg 102(4):1067–1073. https://doi.org/10.1016/j.athoracsur.2016.04.056 CrossRefGoogle Scholar
- 5.Auperin A, Le Pechoux C, Rolland E, Curran WJ, Furuse K, Fournel P, Belderbos J, Clamon G, Ulutin HC, Paulus R, Yamanaka T, Bozonnat MC, Uitterhoeve A, Wang X, Stewart L, Arriagada R, Burdett S, Pignon JP (2010) Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol 28(13):2181–2190. https://doi.org/10.1200/JCO.2009.26.2543 CrossRefGoogle Scholar
- 6.Curran WJ Jr., Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, Movsas B, Wasserman T, Rosenthal SA, Gore E, Machtay M, Sause W, Cox JD (2011) Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst 103(19):1452–1460. https://doi.org/10.1093/jnci/djr325 CrossRefPubMedPubMedCentralGoogle Scholar
- 7.Roy S, Pathy S, Mohanti BK, Raina V, Jaiswal A, Kumar R, Kalaivani M (2016) Accelerated hypofractionated radiotherapy with concomitant chemotherapy in locally advanced squamous cell carcinoma of lung: evaluation of response, survival, toxicity and quality of life from a Phase II randomized study. Br J Radiol 89(1062):20150966. https://doi.org/10.1259/bjr.20150966 CrossRefPubMedPubMedCentralGoogle Scholar
- 9.Steuer CE, Behera M, Ernani V, Higgins KA, Saba NF, Shin DM, Pakkala S, Pillai RN, Owonikoko TK, Curran WJ, Belani CP, Khuri FR, Ramalingam SS (2016) Comparison of concurrent use of thoracic radiation with either carboplatin-paclitaxel or cisplatin-etoposide for patients with stage III non-small-cell lung cancer: a systematic review. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2016.4280 CrossRefGoogle Scholar
- 13.Lu B, Sun L, Yan X, Ai Z, Xu J (2015) Intratumoral chemotherapy with paclitaxel liposome combined with systemic chemotherapy: a new method of neoadjuvant chemotherapy for stage III unresectable non-small cell lung cancer. Med Oncol 32(1):345. https://doi.org/10.1007/s12032-014-0345-5 CrossRefPubMedGoogle Scholar
- 14.Wang X, Zhou J, Wang Y, Zhu Z, Lu Y, Wei Y, Chen L (2010) A phase I clinical and pharmacokinetic study of paclitaxel liposome infused in non-small cell lung cancer patients with malignant pleural effusions. Eur J Cancer 46(8):1474–1480. https://doi.org/10.1016/j.ejca.2010.02.002 CrossRefPubMedGoogle Scholar
- 17.Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92(3):205–216. https://doi.org/10.1093/jnci/92.3.205 CrossRefPubMedGoogle Scholar
- 19.Tell R, Sederholm C, Klintenberg C, Franksson L, Branden E, Hillerdal G, Lonn U, Linden CJ, Ewers SB, Lamberg K, Mrazek E, Loden B, Sjogren A, Linne T, Friesland S, Sirzen F (2008) Multicentre phase II trial of paclitaxel and carboplatin with concurrent radiotherapy in locally advanced non-small cell lung cancer. Anticancer Res 28(5B):2851–2857PubMedGoogle Scholar
- 20.Jazieh AR, Younas A, Safa M, Redmond K, Buncher R, Howington J (2007) Phase I clinical trial of concurrent paclitaxel, carboplatin, and external beam chest irradiation with glutamine in patients with locally advanced non-small cell lung cancer. Cancer Investig 25(5):294–298. https://doi.org/10.1080/07357900701208758 CrossRefGoogle Scholar
- 21.Vokes EE, Herndon JE 2nd, Kelley MJ, Cicchetti MG, Ramnath N, Neill H, Atkins JN, Watson DM, Akerley W, Green MR, Cancer, Leukemia Group B (2007) Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: cancer and Leukemia Group B. J Clin Oncol Off J Am Soc Clin Oncol 25(13):1698–1704. https://doi.org/10.1200/JCO.2006.07.3569 CrossRefGoogle Scholar
- 23.Wang HY, Zhang XR (2014) Comparison of efficacy and safety between liposome-paclitaxel injection plus carboplatin and paclitaxel plus carboplatin as first line treatment in advanced non-small cell lung cancer. Zhongguo yi xue ke xue yuan xue bao. Acta Acad Med Sin 36(3):305–308. https://doi.org/10.3881/j.issn.1000-503X.2014.03.014 CrossRefGoogle Scholar
- 24.Aoyama T, Takano M, Miyamoto M, Yoshikawa T, Soyama H, Kato K, Ishibashi H, Iwahashi H, Nakatsuka M, Yajima I, Shimizu Y, Aizawa Y, Suguchi Y, Moriiwa M, Goto T, Sasa H, Nagaoka I, Tsuda H, Furuya K (2017) Is there any predictor for hypersensitivity reactions in gynecologic cancer patients treated with paclitaxel-based therapy? Cancer chemother Pharmacol 80(1):65–69. https://doi.org/10.1007/s00280-017-3332-7 CrossRefPubMedGoogle Scholar
- 25.Ratanajarusiri T, Sriuranpong V, Sitthideatphaiboon P, Poovoravan N, Vinayanuwat C, Parinyanitikul N, Angspatt P, Thawinwisan W, Tanasanvimon S (2017) A difference in the incidences of hypersensitivity reactions to original and generic taxanes. Chemotherapy 62(2):134–139. https://doi.org/10.1159/000450748 CrossRefPubMedGoogle Scholar
- 26.Zhang Z, Xu J, Zhou T, Yi Y, Li H, Sun H, Huang W, Wang D, Li B, Ying G (2014) Risk factors of radiation-induced acute esophagitis in non-small cell lung cancer patients treated with concomitant chemoradiotherapy. Radiat Oncol 9:54. https://doi.org/10.1186/1748-717X-9-54 CrossRefPubMedPubMedCentralGoogle Scholar